Design, Synthesis and Biological Activity of New Amides Derived from 3-Benzhydryl and 3-sec-Butyl-2,5-dioxo-pyrrolidin-1-yl-acetic Acid.


Journal

ChemMedChem
ISSN: 1860-7187
Titre abrégé: ChemMedChem
Pays: Germany
ID NLM: 101259013

Informations de publication

Date de publication:
18 05 2021
Historique:
revised: 26 01 2021
received: 29 12 2020
pubmed: 5 2 2021
medline: 7 1 2022
entrez: 4 2 2021
Statut: ppublish

Résumé

The aim of this study was to design and synthesize two new series of pyrrolidine-2,5-dione-acetamides with a benzhydryl or sec-butyl group at position 3 as potential anticonvulsants. Their anticonvulsant activity was evaluated in standard animal models of epilepsy: the maximal electroshock (MES), the 6 Hz, and the subcutaneous pentylenetetrazole (scPTZ) tests. The in vivo studies revealed the most potent anticonvulsant activity for 15 (3-(sec-butyl)-1-(2-(4-(3-trifluoromethylphenyl)piperazin-1-yl)-2-oxoethyl)pyrrolidine-2,5-dione), with ED

Identifiants

pubmed: 33539029
doi: 10.1002/cmdc.202001007
doi:

Substances chimiques

Amides 0
Analgesics 0
Antineoplastic Agents 0
Formaldehyde 1HG84L3525
Acetic Acid Q40Q9N063P

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1619-1630

Subventions

Organisme : Jagiellonian University Medical College
ID : K/ZDS/007864
Organisme : Jagiellonian University Medical College
ID : K/DSC/005295
Organisme : Jagiellonian University Medical College
ID : N42/DBS/000048
Organisme : National Science Centre, Poland
ID : 2017/25/B/NZ7/01048

Informations de copyright

© 2021 Wiley-VCH GmbH.

Références

E. Giourou, A. Stavropoulou-Deli, A. Giannakopoulou, G. K. Kostopoulos, M. Koutroumanidis, Introduction to Epilepsy and Related Brain Disorders in Cyberphysical Systems for Epilepsy and Related Brain Disorders. Springer International Publishing, 2015, 11-38.
K. Łukawski, M. Andres-Mach, M. Czuczwar, J. J. Łuszczki, K. Kruszyński, S. J. Czuczwar, Pharmacol. Rep. 2018, 70, 284-293.
J. J. Luszczki, Pharmacol. Rep. 2009, 61, 197-216.
M.-C. Picot, M. Baldy-Moulinier, J.-P. Daurès, P. Dujols, A. Crespel, Epilepsia 2008, 49, 1230-1238.
W. Löscher, D. Schmidt, Epilepsia 2011, 52, 657-678.
M. J. Brodie, A. Covanis, A. Gil-Nagel, H. Lerche, E. Perucca, G. J. Sills, H. S. White, Epilepsy Behav. 2011, 21, 331-341.
H. N. Khan, S. Kulsoom, H. Rashid, Epilepsy Res. 2012, 98, 62-71.
J. Obniska, A. Rapacz, S. Rybka, M. Góra, P. Żmudzki, K. Kamiński, Arch. Pharm. 2017, 350, 1600368.
S. Rybka, J. Obniska, A. Rapacz, B. Filipek, P. Żmudzki, Bioorg. Med. Chem. Lett. 2017, 27, 1412-1415.
J. Obniska, I. Chlebek, K. Kamiński, J. Karolak-Wojciechowska, Arch. Pharm. 2013, 346, 71-82.
J. Obniska, A. Rapacz, S. Rybka, M. Góra, K. Kamiński, K. Sałat, P. Żmudzki, Bioorg. Med. Chem. 2016, 24, 1598-1607.
A. Czopek, H. Byrtus, A. Zagórska, J. Rychtyk, M. Góra, K. Sałat, A. Rapacz, J. Obniska, Bioorg. Med. Chem. Lett. 2019, 29, 2387-2392.
S. Rybka, J. Obniska, A. Rapacz, B. Filipek, P. Żmudzki, J. Enzyme Inhib. Med. Chem. 2016, 31, 1038-1047.
M. A. Rogawski, W. Löscher, Nat. Med. 2004, 10, 685-692.
M. Bialer, Epilepsia 2012, 53 Suppl 7, 26-33.
A. Rapacz, S. Rybka, J. Obniska, A. Jodłowska, M. Góra, P. Koczurkiewicz, E. Pękala, A. Siwek, B. Filipek, Eur. J. Pharmacol. 2020, 869, 172890.
A. Rapacz, J. Obniska, B. Wiklik-Poudel, S. Rybka, K. Sałat, B. Filipek, Eur. J. Pharmacol. 2016, 781, 239-249.
C. A. Miller, L. Long’, J. Am. Chem. Soc. 1951, 73, 4895-4898.
SwissAdme, available online: http://www.swissadme.ch/ (accessed on 25. 08. 2020).
C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Adv. Drug Delivery Rev. 2001, 46, 3-26.
D. F. Veber, S. R. Johnson, H.-Y. Cheng, B. R. Smith, K. W. Ward, K. D. Kopple, J. Med. Chem. 2002, 45, 2615-2623.
M. Bialer, H. S. White, Nat. Rev. Drug Discovery 2010, 9, 68-82.
M. Smith, K. S. Wilcox, H. S. White, Neurotherapeutics 2007, 4, 12-17.
M. M. Castel-Branco, G. L. Alves, I. V. Figueiredo, A. C. Falcão, M. M. Caramona, Methods Find. Exp. Clin. Pharmacol. 2009, 31, 101-106.
W. Löscher, Seizure Eur. J. Epilep. 2011, 20, 359-368.
R. Thirumurugan, D. Sriram, A. Saxena, J. Stables, P. Yogeeswari, Bioorg. Med. Chem. 2006, 14, 3106-3112.
“Discovery and Preclinical Development of Antiepileptic Drugs”, S. H. White, J. H. Woodhead, K. S. Wilcox, J. P. Stables, H. J. Kupferberg, H. H. Wolf, in: Antiepileptic Drugs 5th ed. (Eds.: R. H. Levy, R. H. Mattson, B. S. Meldrum, E. Perucca), Lippincott, Williams and Wilkins, Philadelphia, 2002, pp. 36-48.
M. Abram, M. Zagaja, S. Mogilski, M. Andres-Mach, G. Latacz, S. Baś, J. J. Łuszczki, K. Kieć-Kononowicz, K. Kamiński, J. Med. Chem. 2017, 60, 8565-8579.
G. Brown, J. Neurosci. 1986, 6, 2064-2070.
R. J. Gould, K. M. Murphy, S. H. Snyder, Proc. Natl. Acad. Sci. USA 1982, 79, 3656-3660.
T. M. Laughlin, K. V. Tram, G. L. Wilcox, A. K. Birnbaum, J. Pharmacol. Exp. Ther. 2002, 302, 1168-1175.
J. Milano, S. M. Oliveira, M. F. Rossato, P. D. Sauzem, P. Machado, P. Beck, N. Zanatta, M. A. Martins, C. F. Mello, M. A. Rubin, J. Ferreira, H. G. Bonacorso, Eur. J. Pharmacol. 2008, 581, 86-96.
W. Masocha, S. B. Kombian, I. O. Edafiogho, Sci. Rep. 2016, 6, 21582.
X. K. Wang, Acta Pharmacol. Sin. 2001, 22, 521-523.
T. Hurrell, A. A. Ellero, Z. F. Masso, A. D. Cromarty, Toxicol. in Vitro 2018, 50, 86-94.
J. Obniska, A. Rapacz, S. Rybka, B. Powroźnik, E. Pękala, B. Filipek, P. Żmudzki, K. Kamiński, Eur. J. Med. Chem. 2015, 102, 14-25.
J. T. Litchfield, F. Wilcoxon, J. Pharmacol. Exp. Ther. 1949, 96, 99-113.
A. Rapacz, K. Kamiński, J. Obniska, P. Koczurkiewicz, E. Pękala, B. Filipek, Naunyn-Schmiedeberg′s Arch. Pharmacol. 2017, 390, 567-579.
A. Rapacz, J. Obniska, B. Wiklik-Poudel, S. Rybka, K. Sałat, B. Filipek, Eur. J. Pharmacol. 2016, 781, 239-249.
T. M. Laughlin, K. V. Tram, G. L. Wilcox, A. K. Birnbaum, J. Pharmacol. Exp. Ther. 2002, 302, 1168-1175.
A. Rapacz, M. Głuch-Lutwin, B. Mordyl, B. Filipek, M. Abram, K. Kamiński, Epilepsy Res. 2018, 143, 11-19.

Auteurs

Małgorzata Góra (M)

Department of Medicinal Chemistry, Jagiellonian University Medical College, Faculty of Pharmacy, Medyczna 9, 30-688, Kraków, Poland.

Anna Czopek (A)

Department of Medicinal Chemistry, Jagiellonian University Medical College, Faculty of Pharmacy, Medyczna 9, 30-688, Kraków, Poland.

Anna Rapacz (A)

Department of Pharmacodynamics, Jagiellonian University Medical College, Faculty of Pharmacy, Medyczna 9, 30-688, Kraków, Poland.

Agnieszka Giza (A)

Department of Pharmacodynamics, Jagiellonian University Medical College, Faculty of Pharmacy, Medyczna 9, 30-688, Kraków, Poland.

Paulina Koczurkiewicz-Adamczyk (P)

Department of Pharmaceutical Biochemistry, Jagiellonian University Medical College, Faculty of Pharmacy, Medyczna 9, 30-688, Kraków, Poland.

Elżbieta Pękala (E)

Department of Pharmaceutical Biochemistry, Jagiellonian University Medical College, Faculty of Pharmacy, Medyczna 9, 30-688, Kraków, Poland.

Jolanta Obniska (J)

Department of Medicinal Chemistry, Jagiellonian University Medical College, Faculty of Pharmacy, Medyczna 9, 30-688, Kraków, Poland.

Krzysztof Kamiński (K)

Department of Medicinal Chemistry, Jagiellonian University Medical College, Faculty of Pharmacy, Medyczna 9, 30-688, Kraków, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH